KLOW80 is a multi‑peptide formulation combining 80 mg in total of 50 mg GHK‑Cu + 10 mg BPC‑157 + 10 mg TB‑500 + 10 mg KPV in a single lyophilized vial. This synergistic blend is formulated to support collagen synthesis, accelerate tissue repair, reduce inflammation and promote gut and musculoskeletal recovery in preclinical and laboratory studies.
Key Features
- Four‑component regenerative peptide blend (GHK‑Cu + BPC‑157 + TB‑500 + KPV)
- Designed to enhance collagen production, angiogenesis, actin‑mediated tissue repair and anti‑inflammatory responses
- Supports skin repair, tendon/ligament healing, muscle regeneration and gut integrity
- Supplied lyophilized to allow controlled reconstitution and dosing
- Ideal for regenerative medicine, musculoskeletal and anti‑aging.
Product Specifications
- Product name: KLOW80 (peptide blend) (Purity: 99+% HPLC)
- Composition per vial (80 mg): GHK‑Cu 50mg + BPC‑157 10mg + TB‑500 10mg + KPV 10mg
- Category: Regenerative peptide blend
- Supplied as: Lyophilized powder in sterile vial + 3 ml bac water
- Administration (research/preclinical): Subcutaneous injection (typical)
- Storage (reconstituted): Keep at 2–8 °C
Mechanism of Action (Research Summary)
- GHK‑Cu: copper‑binding tripeptide that stimulates collagen synthesis and extracellular matrix remodeling.
- BPC‑157: peptide reported to promote angiogenesis and support tissue healing and gut integrity.
- TB‑500 (Thymosin β‑4 fragment): facilitates actin polymerization and cellular migration for repair processes.
- KPV: short anti‑inflammatory peptide that can modulate pro‑inflammatory cytokine activity.
Combined, these components target complementary pathways involved in tissue repair, remodeling and inflammation reduction.
Potential Research Applications
- Dermal wound healing and skin regeneration studies
- Tendon, ligament and muscle repair in musculoskeletal models
- Anti‑inflammatory and gut integrity research
- Regenerative medicine and anti‑aging investigations
- Combination protocols with physiotherapy, biomaterials or adjunctive therapeutics
Reconstitution and Dosing Guide
Important: The following examples are for laboratory reference only. Confirm calculations, aseptic technique and solvent compatibility with your institutional protocols before use.
Example reconstitution (80 mg vial + 3.0 mL bacteriostatic water)
- Approximate concentration: 26.7 mg total peptide per mL
- Example dosing volumes (U‑100 insulin syringe reference):
- 3 mg total = 0.11 mL (≈11 units)
- 4 mg total = 0.15 mL (≈15 units)
Suggested Research Protocol
- Typical investigational dose: 3–4 mg total per administration (adjust per study design)
- Frequency: once daily or 5 times per week
- Cycle length examples: 4–8 weeks on with 2–8 weeks off
- Tapering: generally not required for short cycles
- Combine with rehabilitative interventions (exercise, physiotherapy) for synergistic effects
Research Insights
- The blend pairs peptides that promote collagen production, angiogenesis, cellular migration and anti‑inflammatory signaling — a multi‑modal approach often used in regenerative research.
- Reported experimental endpoints include accelerated wound closure, improved tendon/ligament healing, reduced local inflammation and improved markers of tissue remodeling in controlled models.
Possible Observations and Adverse Events
- Mild local injection site irritation (reported rarely)
- Mild gastrointestinal discomfort if oral/topical routes are explored (very rare)
- No major systemic adverse events commonly reported in preclinical literature; however, individual components should be assessed for safety in the chosen model
Storage, Stability and Handling After Reconstitution
- Reconstituted solutions: keep at 2–8 °C and protect from light
- Minimize freeze–thaw cycles and employ sterile technique throughout handling
Safety and Handling
- Follow institutional biosafety, handling and waste disposal protocols.
Frequently Asked Questions
Q: Is 3 mg a suitable starting research dose?
A: 3 mg total is commonly used as an investigational starting point in combination protocols; dose selection should follow study design and institutional approval.
Q: Can the blend be used long‑term?
A: Cycling is often recommended to balance efficacy, cost and theoretical exposure; study‑specific guidance should be followed.
Q: How soon might effects be observed?
A: Tissue repair and anti‑inflammatory benefits may be measurable within weeks in controlled experimental models, depending on endpoints and concomitant therapies.
Legal and Regulatory Notice
By purchasing this product you confirm that you are acquiring it for lawful research purposes. It is the purchaser’s responsibility to ensure compliance with local laws, institutional policies, ethical and customs requirements. Liability for misuse is disclaimed.
